Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?

Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year over year, and Merck’s Q3 sales consensus is $7.45 billion; management targets $35 billion in peak sales by 2028. Growth may benefit from earlier-stage launches and label expansions, but biosimilar competition around 2028–2029 could sharply reduce sales. Merck shares are up 37.7% year to date, while consensus EPS estimates for 2026 and 2027 have fallen to $2.66 and $9.27, respectively, and Zacks rates the stock Sell.

Analysis

The key asymmetry is not whether Keytruda remains a large franchise, but whether incremental growth can justify expectations after MRK’s sharp YTD rerating. A Q3 sales beat could be a weak catalyst if it reflects pull-forward or pricing rather than durable patient starts; watch volume, earlier-stage uptake and management’s 2028 trajectory, not just the $7.45B consensus. Qlex may help preserve treatment convenience and clinic capacity, but its first-half contribution alone does not establish that it can offset biosimilar erosion.

Over 1–3 months, the Oct. 29 report is the catalyst; a miss, softer forward commentary or further EPS estimate cuts could expose MRK’s run-up. Over 6–18 months, the market may increasingly discount the 2028–29 exclusivity cliff, while new indications and formulation switching could cushion—but cannot be assumed to prevent—erosion. AZN’s Imfinzi growth is a relative competitive signal, not proof of direct share capture from Keytruda; BMY’s Opdivo decline is a weaker counterpoint. Pfizer may benefit from Padcev demand in the cited combination, but the article provides no revenue sensitivity to quantify it.

Contrarian angle: the apparent forward-P/E discount to the industry may be a value trap if earnings estimates keep falling and the market begins valuing the post-Keytruda business rather than peak sales. Conversely, biosimilar timing, substitution and net pricing are not established here, so avoid treating the patent cliff as an immediate cliff in quarterly revenue.

Key Decisions for Investors

• Keep MRK neutral-to-underweight into Oct. 29 rather than chase the rally; add exposure only if results show broad-based demand and management sustains the path toward peak sales without further estimate deterioration.
• For a 1–3 month relative-value expression, consider a small long AZN / short BMY pair: it targets the divergence in reported Imfinzi and Opdivo momentum, not a claim that their products are interchangeable. Reassess if AZN’s oncology growth decelerates or BMY reports a clear Opdivo stabilization.
• Track Q3 Keytruda volume, price/mix, Qlex adoption, earlier-stage launch uptake and any update to biosimilar timing or expected erosion. These are the missing details needed before assigning value to lifecycle defenses.
• Falsify the cautious MRK view if Q3 growth is broad-based and forward guidance or consensus EPS revisions turn upward; strengthen it if sales disappoint versus $7.45B, guidance weakens, or estimates continue to fall.